CollPlant Biotechnologies (CLGN) Change in Accured Expenses (2018 - 2026)
CollPlant Biotechnologies (CLGN) reported Change in Accured Expenses of -$235000.0 for Q1 2026, down 144.79% on a YoY basis from $524651.2 in Q1 2025, and down 1168.18% quarter-over-quarter from $22000.0 in Q4 2025.
CollPlant Biotechnologies (CLGN) Change in Accured Expenses (2018 - 2026) Analysis & Trends
CollPlant Biotechnologies has reported Change in Accured Expenses for 9 years, with the latest figure at -$235000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 144.79% year-over-year to -$235000.0; the trailing twelve-month figure through Mar 2026 stood at -$185000.0 (up 63.73% YoY), and the FY2025 full-year result was -$46000.0, up 86.97% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$235000.0, down from $22000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $476000.0 in Q4 2022, with the low at -$394000.0 in Q2 2024.
- Historically, Change in Accured Expenses has averaged -$24470.6 across 5 years, with a median of -$52000.0 in 2024.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 202.59% — and 2023, when it sank 414.29%.
- CollPlant Biotechnologies' Change in Accured Expenses stood at $476000.0 in 2022, then plunged by 31.09% to $328000.0 in 2023, then slumped by 90.24% to $32000.0 in 2024, then plunged by 31.25% to $22000.0 in 2025, then tumbled by 1168.18% to -$235000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$235000.0 (Q1 2026), $22000.0 (Q4 2025), and -$108000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | CollPlant Biotechnologies | 7.20 Mn | 7.20 Mn | - | -235,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -235,000.00 |
| Mar 31, 2026 | -235,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Sep 30, 2025 | -108,000.00 |
| Sep 30, 2025 | -108,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | -96,000.00 |
| Mar 31, 2025 | -96,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | -52,000.00 |
| Sep 30, 2024 | -52,000.00 |
| Jun 30, 2024 | -394,000.00 |
| Jun 30, 2024 | -394,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Dec 31, 2023 | 328,000.00 |
| Dec 31, 2023 | 328,000.00 |